HER2-Low Breast Carcinoma — Trials

HER2-Low Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

24 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 14
Recruiting: 12
Ph III recruiting: 1
Growth YoY: —
Industry share: 14%
Top sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06733233	A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer	not yet recruiting	Phase 2	23	Guangzhou Women and Children's Medical CenterOTHER	0	Dec 13, 2024	clinicaltrials

Data updated 22 days agoSource updated Dec 13, 2024source: clinicaltrials